Bristol's Opdivo/Yervoy Bid Will Show Whether Tumor Mutation Burden Is Ready For Prime Time

US FDA officials have supported tumor mutation burden as a biomarker, but analysts question whether a subset analysis of CheckMate 227 will be enough to support approval of Bristol's Opdivo/Yervoy combination in first-line lung cancer.

chess

Bristol-Myers Squibb Co.'s surprise announcement that its Phase III CheckMate 227 first-line lung cancer study succeeded, but in a subset analysis that had not been prospectively defined, left one burning question – does the company have enough to file for approval? Management suggests the answer is yes, but some leading analysts have doubts.

The CheckMate 227 study is a multi-arm trial evaluating Bristol's PD-1 inhibitor Opdivo (nivolumab) with its CTLA-4 inhibitor Yervoy (ipilimumab)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet